• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen announces new publication in Nature Chemistry

by Lisa Nadal | Jul 4, 2023 | Press Releases

The study was conducted by scientists at Philochem AG, the wholly owned Swiss subsidiary company of the Philogen group. The paper can be accessed on the Nature Chemistry website at the following link. Nat_chem_280223_press_release

Philochem will be attending the 10th World ADC Conference in London

by last | Nov 13, 2022 | 2020, Press Releases

Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small Molecule-DrugConjugates: Getting small to enhance targeting” Jacopo Millul...

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

by Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors.   The...

Philogen publishes a new study on OncoFAP in Clinical Cancer Research

by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific

The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...

Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.

by Lisa Nadal | Sep 15, 2022 | 2022, Press Releases, Scientific

The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

by m.romi | Jul 25, 2022 | 2022, Press Releases, Scientific

More details
« Older Entries

Recent Posts

  • Philogen announces new publication in Nature Chemistry
  • Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch